Hormonal
Daily administration of the selective androgen receptor modulator GTx-024 (enobosarm) at 3 mg significantly increases total lean body mass and improves physical function in healthy elderly men and postmenopausal women without causing adverse androgenic side effects.
For healthy older adults looking to build muscle, a daily 3mg dose of the SARM GTx-024 (enobosarm) taken for 12 weeks significantly increases lean body mass and physical function without the typical side effects of testosterone therapy. This intervention works best when combined with maintaining your current diet and exercise habits, as the drug itself drives the anabolic response.
GTx-024 treatment resulted in dose-dependent increases in total lean body mass that were statistically significant (P<0.001, 3 mg vs. placebo) and clinically meaningful. There were also significant improvements in physical function (P=0.013, 3 mg vs. placebo)... GTx-024 showed a dose-dependent improvement in total lean body mass and physical function and was well tolerated.
Why this rating
Phase II, randomized, double-blind, placebo-controlled clinical trial with a moderate sample size (n=120) and clear statistical significance.
Source
The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial
James T. Dalton et al. · Journal of Cachexia Sarcopenia and Muscle · 2011
DOI 10.1007/s13539-011-0034-6
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →